As a matter of fact, existing SARS-CoV-2 infection (but probably also COVID-19 treatments) may promote viral reactivations and coinfections by impairing cellular immunity (with significant loss of lymphocytes or natural killer (NK) cells, and reduction or exhaustion of functional T cells with altered CD4+/CD8+ ratio). This evidence concerns the gene CD8A and COVID-19.